Peptide and Anticoagulant Drugs

Peptide and Anticoagulant Drugs

Peptides are a combination of two or more amino acid monomers linked by amino acids. They act as efficient signaling molecules which bind to specific cell surface receptors, including ion channels and G protein-coupled receptors, and trigger intracellular effects. Anticoagulants are also called blood thinners and are used for treating and preventing blood clots which can block blood vessels. Researchers are actively utilizing peptides for the development of novel formulations indicated for the management of a wide range of acute and chronic diseases. According to the American Cancer Society, "Cancer and Figures 2022", there was an estimated 1.9 million new cancer cases diagnosed in 2022. Moreover, as per the same source in 2020, the most common cancers were breast (253,465), lung (227,875), prostate (209,512), and colon (101,809) in the U.S. Thus, the increasing cases of cancer require early treatment which is expected to increase the demand for peptide therapeutics over the forecast period.

The Peptide and anticoagulant drugs Market is expected to grow at a strong CAGR of 4.5% during the forecast period owing to the rising pharmaceutical investment for the development of novel drugs. For instance, in September 2021, Nimble Therapeutics collaborated with Incyte to discover novel peptide therapeutics. Further in July 2020, IRBM merged with Merck for the development of advanced peptide therapeutics. Such investments are expected to drive the market growth in the coming years.

• Based on application, the market is segmented into cancer, metabolic, cardiovascular disorders, pulmonary embolism, deep vein thrombosis, atrial fibrillation & heart attack, and others. Amongst these, cancer is expected to grow with a high CAGR during the forecast period owing to the high specificity and targetability of peptide therapeutics. Other factors, such as a surge in the prevalence of cancer, rapid product launches, and increasing research and development activities are also driving the segment growth. For instance, in June 2021, Nimble Therapeutics announced a collaboration with RayzeBio to discover and develop novel peptide-based radiopharmaceuticals for the treatment of cancer.
• By route of administration, the market is segmented into peptide drugs which are sub-segmented into parental, mucosal, oral, and transdermal, and anticoagulant drugs sub-segmented into oral and injectable. Among these, the parental category held a dominant share of the market in 2021. Several factors, such as high adoption rate, faster delivery of drugs, and ease of application are the major reasons for increasing their adoption in the global market. Currently, the majority of peptide therapeutics are delivered by parental route, which is also driving the market growth during the coming years.
• On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Online pharmacies are expected to register a high CAGR during the forecast period. The demand for the online pharmacy segment is projected to be influenced by factors such as the rise in internet usage, rising telemedicine adoption, rising technology adoption, and convenience and time efficiency. Also, the availability of well-known e-pharmacy players and the savings they provide are expected to support segment demand in the near future.
• For a better understanding of the market adoption of the Peptide and anticoagulant drugs industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America held a dominant share in the market in 2021 owing to the increased adoption of targeted therapy and the rise in the incidence of cancer in the U.S. According to the Globocan 2020 report, an estimated 2,281,658 new cancer cases were diagnosed in the U.S. in 2020, with nearly 612,390 deaths. Apart from this, the presence of major key players, rising investments by pharmaceutical companies, and favorable government regulatory policies are also propelling regional market growth. For instance, in July 2022, Peptilogics received U.S. FDA fast-track designation for PLG0206, for the treatment of periprosthetic joint infection (PJI).
• Some of the major players operating in the market include AbbVie Inc.; F. Hoffmann-La Roche Ltd; Amgen Inc.; Pfizer Inc.; Bristol-Myers Squibb Company; Lilly; Sanofi; GSK plc; Novartis AG; and Takeda Pharmaceutical Company Limited.